PDCD1 and lung adenocarcinoma: The anti-TIM-3 mAb has been shown to increase the resistance of anti-PD-1 therapy in mouse models of lung adenocarcinoma with genetically engineered EGFR and extended the median survival from 5 to 11.9 weeks.